BioCryst Swings to $263.9M Profit, Guides $635M-$660M Sales
BioCryst swung to a $263.9M net profit in 2025 from an $88.9M loss in 2024 as revenues rose 94% to $874.8M, aided by a $243.3M sale of its European Orladeyo unit. Q4 saw $245.8M profit versus a $26.8M loss as revenues tripled to $406.5M; it projects $635M-$660M sales in 2026.
1. Profitability Turnaround in 2025
BioCryst reversed an $88.9 million net loss in 2024 to record $263.9 million in net income for 2025, marking its first full-year profit. Total revenues climbed 94% year-over-year to $874.8 million, bolstered by the €243.3 million sale of its European Orladeyo unit and increased new patient prescriptions in the US.
2. Fourth Quarter Performance
In Q4 2025, BioCryst posted a net income of $245.8 million compared with a $26.8 million loss in Q4 2024. Revenues surged to $406.5 million, more than triple the prior year’s figure, driven by strong Orladeyo uptake and expanded commercial outreach.
3. 2026 Financial Guidance
The company forecasts total revenues of $635 million to $660 million for 2026, with $625 million to $645 million expected from Orladeyo sales. This guidance assumes continued prescription momentum and stable market access for hereditary angioedema treatment.